Jon Faiz Kayyem
Jon Faiz Kayyem has made 2 open-market purchases worth $1.0M since Sep 17, 2026, in 1 company. The latest: $500k of INBX, filed Sep 23, 2026, scored 45 out of 100.
Director, Inhibrx Biosciences, Inc.
Follow Jon Faiz Kayyem, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Purchases
| Filed | Stock | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Sep 23 Form 4 (opens sec.gov) |
INBXInhibrx Biosciences, Inc. · DirectorDirector · 2 insiders buying | +1% stake | 45 | $500k 5,000 at $100.00 |
−2.5% | −11.7% |
| Sep 17 Form 4 (opens sec.gov) |
INBXInhibrx Biosciences, Inc. · DirectorDirector | +1% stake | 33 | $500k 5,000 at $100.00 |
−8.9% | −17.9% |
Track record (hypothetical): a week after the filing, these buys averaged −5.7% (0% up, 2 measured); a month after, −14.8% (0% up, 2 measured).
Questions
What stock has Jon Faiz Kayyem bought?
INBX (Inhibrx Biosciences, Inc.), all on the open market and reported on SEC Form 4.
When did Jon Faiz Kayyem last buy?
Sep 23, 2026: 5,000 shares of INBX at $100.00, $500k in all (Form 4 (opens sec.gov)).
Has Jon Faiz Kayyem filed a notice of a planned sale?
Not in the filings on record. A Form 144 is the notice an insider must file before selling restricted or control shares, and it lands on EDGAR before the sale is reported.
Is Jon Faiz Kayyem a routine or an opportunistic buyer?
There isn't enough history to say yet.
Data as of Sep 23, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer